Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Hepatitis C Point-of-Care Tests Are Highly Accurate

By LabMedica International staff writers
Posted on 30 Oct 2012
Point-of-care tests (POCTs) for the diagnosis of hepatitis C (HCV) have a high level of accuracy and may help increase screening rates for this disease. More...


Convenient, quality-assured, antibody-based rapid diagnostic tests (RDTs) and POCTs could facilitate preliminary screening, although they cannot differentiate between acute and chronic infections and their rapid turnaround time limits loss to follow-up and facilitates early associations.

Although both diagnostic test types are rapid, RDTs require special equipment, such as centrifuges and refrigerators, whereas POCTs eliminate the need for electricity and are more robust at high temperatures, thus offering additional opportunities to expand screening. A meta-analysis carried out by scientists at McGill University Health Center (Montreal, QC, Canada) reviewed 19 studies conducted between 1992 and 2012 that screened for HCV in adults. All the studies had evaluated the diagnostic accuracy of POCTs and RDTs that screen for HCV in oral fluid, whole blood, serum, or plasma.

The investigators found that POCTs had the highest sensitivity for whole blood at 98.9% and serum or plasma also at 98.9%. The RDTs of serum or plasma had the next-highest sensitivity of 98.4%, followed by POCTs of oral fluid at 97.1%.

Specificity of POCTs of whole blood and serum or plasma was also high, at 99.5% and 99.7%, respectively. The specificity of RDTs of serum or plasma followed, at 98.6%, and then the specificity of POCTs of oral fluid, at 98.2%.

The authors notes that because the tests evaluated in this meta-analysis detected antibodies to HCV, these POCTs could not differentiate between acute and chronic infections and could not detect infection within three months of exposure. Cases with possible false negative or false-positive results would require further screening, which may depend on available resources.

The authors concluded that given the convenience of POCTs and their rapid turnaround time, these results show great potential for expanded first-line screening for hepatitis C infection and demonstrate the utility of blood-based singleton POCTs and of multiplex POCTs designed to provide integrated HIV and HCV screening of at-risk populations. The study was published on October 16, 2012, in the journal Annals of Internal Medicine.

Related Links:
McGill University Health Center


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.